
ROIV Stock Forecast & Price Target
ROIV Analyst Ratings
Bulls say
Roivant Sciences is expected to see continued success in the commercial stage and incubation of discovery-stage companies, with key drug candidates in various stages of development and promising data. With a strong portfolio and plans to engage with the FDA in 2H26, the company demonstrates a commitment to providing innovative solutions for patients and potential for future growth. The valuation is supported by discounted risk-adjusted revenue estimates, with risks including regulatory and commercial challenges.
Bears say
Roivant Sciences is facing a potential delay in the launch of its drug therapy, brepocitinib for the treatment of dermatomyositis (DM), as the FDA has assigned a PDUFA date in 2026. This could negatively impact the company's revenue and profitability in the near term. Additionally, the company's development pipeline faces potential challenges and uncertainties, such as the start of Phase 3 studies and the timing of topline data.
This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.
ROIV Analyst Forecast & Price Prediction
Start investing in ROIV
Order type
Buy in
Order amount
Est. shares
0 shares